HCG to Add 1,000 Beds as It Scales Cancer Care Across Tier-II India

HCG is also investing in next-generation treatment modalities such as MRI-guided linear accelerators, robotic-assisted surgeries, and immunotherapy, alongside integrating artificial intelligence and analytics into its diagnostic and treatment workflows.

HCG has outlined an expansion roadmap into tier-II cities and has committed to adding 1,000 beds over the next five years, increasing its total capacity from around 2,500 to nearly 3,500 beds.

HCG aims to meet rising cancer care demand by combining new hospital developments with expansions at existing centres. The expansion strategy has been structured around both greenfield and brownfield approaches.

Around 400 beds are expected to come from new hospitals, while an additional 500-600 beds will be added by scaling up existing facilities.

With 25 hospitals across 19 cities, including an international presence in Kenya, HCG is now identifying 10-13 new locations such as Pune, Surat, Kolkata, Guwahati, Hyderabad, Chennai, and Coimbatore for further growth.

Alongside organic expansion, the company has kept its inorganic strategy open. Backed by private equity investor KKR, HCG is actively evaluating acquisition opportunities to consolidate its presence in the oncology segment.

“We’re not ruling out mergers and acquisitions. Opportunities for standalone cancer centres or chains do come up, and we will actively evaluate them,” Dr Manish Mattoo, Executive Director and CEO, HCG, said.

Beyond capacity addition, HCG is placing strong emphasis on clinical excellence and technology adoption. The company is investing in next-generation treatment modalities such as MRI-guided linear accelerators, robotic-assisted surgeries, and immunotherapy. These advancements are expected to enhance precision oncology and improve patient outcomes.

Furthermore, HCG is integrating artificial intelligence and analytics into its diagnostic and treatment workflows to enable earlier detection and more personalised care pathways. This aligns with broader trends in digital health, where data-driven decision-making is becoming critical to improving efficiency and outcomes in complex care areas like oncology.

“Clinical differentiation and outcomes will be the real engine of growth. Scale becomes a multiplier only when that foundation is strong,” Mattoo said.

Financially, the company plans to invest approximately INR 200-250 Cr annually while maintaining a focus on operational efficiency and margin improvement.

Stay tuned for more such updates on Digital Health News